{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:40:32Z","timestamp":1792928432014,"version":"4.5.0"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T00:00:00Z","timestamp":1626048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Many broadly neutralizing antibodies (bnAbs) targeting the HIV-1 envelope glycoprotein are being assessed in clinical trials as strategies for HIV-1 prevention, treatment, and antiretroviral-free remission. BnAbs can neutralize HIV-1 and target infected cells for elimination. Concerns about HIV-1 resistance to single bnAbs have led to studies of bnAb combinations with non-overlapping resistance profiles. This review focuses on the potential for bnAbs to induce HIV-1 remission, either alone or in combination with latency reversing agents, therapeutic vaccines or other novel therapeutics. Key topics include preliminary activity of bnAbs in preclinical models and in human studies of HIV-1 remission, clinical trial designs, and antibody design strategies to optimize pharmacokinetics, coverage of rebound-competent virus, and enhancement of cellular immune functions.<\/jats:p>","DOI":"10.3389\/fimmu.2021.710044","type":"journal-article","created":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T08:28:53Z","timestamp":1626078533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?"],"prefix":"10.3389","volume":"12","author":[{"given":"Denise C.","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Mellors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Vasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01.qai.0000233310.90484.16","article-title":"Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study","volume":"43","author":"Palella","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283324283","article-title":"The Effect of Combined Antiretroviral Therapy on the Overall Mortality of HIV-Infected Individuals","volume":"24","author":"HIV-CAUSAL Collaboration","year":"2010","journal-title":"AIDS"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an Inducible HIV-1 Latent Reservoir During Highly Active Antiretroviral Therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV Reservoir Size and Persistence Are Driven by T Cell Survival and Homeostatic Proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000953","article-title":"The Size of the Expressed HIV Reservoir Predicts Timing of Viral Rebound After Treatment Interruption","volume":"30","author":"Li","year":"2016","journal-title":"AIDS"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy479","article-title":"The Control of HIV After Antiretroviral Medication Pause (Champ) Study: Posttreatment Controllers Identified From 14 Clinical Studies","volume":"218","author":"Namazi","year":"2018","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283578b9b","article-title":"Risk Factors, Barriers and Facilitators for Linkage to Antiretroviral Therapy Care: A Systematic Review","volume":"26","author":"Govindasamy","year":"2012","journal-title":"AIDS"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-9942-x","article-title":"Adherence to Highly Active Antiretroviral Therapy (HAART): A Meta-Analysis","volume":"15","author":"Ortego","year":"2011","journal-title":"AIDS Behav"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","article-title":"Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis","volume":"13","author":"Shubber","year":"2016","journal-title":"PloS Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30232-0","article-title":"The Case for an HIV Cure and How to Get There","volume":"8","author":"Dybul","year":"2021","journal-title":"Lancet HIV"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/s41256-019-0107-1","article-title":"The Potential Impact of a \u201cCurative Intervention\u201d for HIV: A Modelling Study","volume":"4","author":"Beacroft","year":"2019","journal-title":"Glob Health Res Policy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30234-4","article-title":"Multi-Stakeholder Consensus on a Target Product Profile for an HIV Cure","volume":"8","author":"Lewin","year":"2021","journal-title":"Lancet HIV"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/science.1187659","article-title":"Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1","volume":"329","author":"Wu","year":"2010","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612","article-title":"Enhanced Neonatal Fc Receptor Function Improves Protection Against Primate SHIV Infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.1207227","article-title":"Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding","volume":"333","author":"Scheid","year":"2011","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0001-2","article-title":"A Single Injection of Crystallizable Fragment Domain-Modified Antibodies Elicits Durable Protection From SHIV Infection","volume":"24","author":"Gautam","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02213-14","article-title":"Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection Against Lentiviral Infection In Vivo","volume":"88","author":"Rudicell","year":"2014","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.10.027","article-title":"Identification of a CD4-Binding-Site Antibody to HIV That Evolved Near-Pan Neutralization Breadth","volume":"45","author":"Huang","year":"2016","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1415789111","article-title":"Recombinant HIV Envelope Trimer Selects for Quaternary-Dependent Antibodies Targeting the Trimer Apex","volume":"111","author":"Sok","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental Pathway for Potent V1V2-Directed HIV-Neutralizing Antibodies","volume":"509","author":"Doria-Rose","year":"2014","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-Type N-Glycan Recognition by Potent Broadly Neutralizing HIV Antibodies","volume":"109","author":"Mouquet","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature10373","article-title":"Broad Neutralization Coverage of HIV by Multiple Highly Potent Antibodies","volume":"477","author":"Walker","year":"2011","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature11544","article-title":"Broad and Potent Neutralization of HIV-1 by a gp41-Specific Human Antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03246-15","article-title":"Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 Through Somatic Variation and Structure-Based Design","volume":"90","author":"Kwon","year":"2016","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","article-title":"Identification and Specificity of Broadly Neutralizing Antibodies Against HIV","volume":"275","author":"McCoy","year":"2017","journal-title":"Immunol Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of Near-Pan-Neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00159-21","article-title":"Rational Engraftment of Quaternary-Interactive Acidic Loops for Anti-HIV-1 Antibody Improvement","volume":"95","author":"Liu","year":"2021","journal-title":"J\u00a0Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, Pharmacokinetics and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411","article-title":"Viraemia Suppressed in HIV-1-Infected Humans by Broadly Neutralizing Antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","article-title":"Virologic Effects of Broadly Neutralizing Antibody VRC01 Administration During Chronic HIV-1 Infection","volume":"7","author":"Lynch","year":"2015","journal-title":"Sci Trans Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 Suppresses Viremia in HIV-1-Infected Individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e1002435","DOI":"10.1371\/journal.pmed.1002435","article-title":"Safety, Pharmacokinetics, and Immunological Activities of Multiple Intravenous or Subcutaneous Doses of an anti-HIV Monoclonal Antibody, VRC01, Administered to HIV-Uninfected Adults: Results of a Phase 1 Randomized Trial","volume":"14","author":"Mayer","year":"2017","journal-title":"PloS Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and Pharmacokinetics of the Fc-Modified HIV-1 Human Monoclonal Antibody VRC01LS: A Phase 1 Open-Label Clinical Trial in Healthy Adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PloS Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and Pharmacokinetics of Broadly Neutralising Human Monoclonal Antibody VRC07-523LS in Healthy Adults: A Phase 1 Dose-Escalation Clinical Trial","volume":"6","author":"Gaudinski","year":"2019","journal-title":"Lancet HIV"},{"key":"B36","article-title":"Therapeutic Activity of PGT121 Monoclonal Antibody in HIV-Infected Adults","volume-title":"Conference on Retroviruses and Opportunistic Infections (Croi)","author":"Stephenson","year":"2019"},{"key":"B37","article-title":"Safety and Virologic Effect of the HIV-1 Broadly Neutralizing Antibodies, VRC01LS or VRC07-523LS, Administered to HIV-Infected Adults in a Phase 1 Clinical Trial","volume-title":"Journal of the International Aids Society","author":"Chen","year":"2019"},{"key":"B38","article-title":"A Phase I Dose-Escalation Trial of Human Monoclonal Antibody N6LS in Healthy Adults","volume-title":"Conference on Retroviruses and Opportunistic Infections (Croi)","author":"Widge","year":"2020"},{"key":"B39","article-title":"Review of bNAbs in Clinical Development","volume-title":"Hiv Research for Prevention Hivr4p, Satellite Session SA04 State of the Art of HIV bNAbs for Prevention of HIV Infection","author":"Koup","year":"2018"},{"key":"B40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","article-title":"Use of Broadly Neutralizing Antibodies for HIV-1 Prevention","volume":"275","author":"Pegu","year":"2017","journal-title":"Immunol Rev"},{"key":"B41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/COH.0000000000000556","article-title":"Neutralizing Antibodies for HIV-1 Prevention","volume":"14","author":"Julg","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-110118-045506","article-title":"Broadly Neutralizing Antibodies for HIV Prevention","volume":"71","author":"Karuna","year":"2020","journal-title":"Annu Rev Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738","article-title":"Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature18929","article-title":"HIV-1 Antibody 3BNC117 Suppresses Viral Rebound in Humans During Treatment Interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180936","article-title":"Relationship Between Latent and Rebound Viruses in a Clinical Trial of anti-HIV-1 Antibody 3BNC117","volume":"215","author":"Cohen","year":"2018","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV Antibody VRC01 on Viral Rebound After Treatment Interruption","volume":"375","author":"Bar","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ebiom.2016.07.024","article-title":"HIV DNA Set Point Is Rapidly Established in Acute HIV Infection and Dramatically Reduced by Early Art","volume":"11","author":"Ananworanich","year":"2016","journal-title":"EBioMedicine"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120248109","article-title":"Immediate Antiviral Therapy Appears to Restrict Resting CD4+ Cell HIV-1 Infection Without Accelerating the Decay of Latent Infection","volume":"109","author":"Archin","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv084","article-title":"Combined ART Started During Acute HIV Infection Protects Central Memory CD4+ T Cells and Can Induce Remission","volume":"70","author":"Cheret","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00007","article-title":"Homogeneous Quasispecies in 16 Out of 17 Individuals During Very Early HIV-1 Primary Infection","volume":"16","author":"Delwart","year":"2002","journal-title":"AIDS"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.2.169","article-title":"Cellular Immune Responses and Viral Diversity in Individuals Treated During Acute and Early HIV-1 Infection","volume":"193","author":"Altfeld","year":"2001","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and Efficacy of VRC01 Broadly Neutralising Antibodies in Adults With Acutely Treated HIV (RV397): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134395","article-title":"Neutralizing Antibody VRC01 Failed to Select for HIV-1 Mutations Upon Viral Rebound","volume":"130","author":"Cale","year":"2020","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1601","article-title":"Enhanced Antibody Half-Life Improves In Vivo Activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature17677","article-title":"A Single Injection of Anti-HIV-1 Antibodies Protects Against Repeated SHIV Challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (Fcrn)","volume":"281","author":"Dall\u2019Acqua","year":"2006","journal-title":"J Biol Chem"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01020-16","article-title":"Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus Aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults","volume":"61","author":"Yu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","article-title":"New Member of the V1V2-Directed Cap256-Vrc26 Lineage That Shows Increased Breadth and Exceptional Potency","volume":"90","author":"Doria-Rose","year":"2016","journal-title":"J Virol"},{"key":"B59","article-title":"Susceptibility to BnAbs Is Concordant in Pre-ART Plasma and On-ART Pbmcs: ACTG Nwc413","volume-title":"Conference on Retroviruses and Opportunistic Infections (Croi)","author":"Reeves","year":"2019"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination Therapy With Anti-HIV-1 Antibodies Maintains Viral Suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03136-14","article-title":"Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes","volume":"89","author":"Kong","year":"2015","journal-title":"J Virol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","article-title":"Potential of Conventional & Bispecific Broadly Neutralizing Antibodies for Prevention of HIV-1 Subtype A, C & D Infections","volume":"14","author":"Wagh","year":"2018","journal-title":"PloS Pathog"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, Pharmacokinetics, and Immunogenicity of the Combination of the Broadly Neutralizing Anti-HIV-1 Antibodies 3BNC117 and 10-1074 in Healthy Adults: A Randomized, Phase 1 Study","volume":"14","author":"Cohen","year":"2019","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.024","article-title":"Engineered Bispecific Antibodies With Exquisite HIV-1-Neutralizing Activity","volume":"165","author":"Huang","year":"2016","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","article-title":"Trispecific Broadly Neutralizing HIV Antibodies Mediate Potent SHIV Protection in Macaques","volume":"358","author":"Xu","year":"2017","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature21435","article-title":"Early Antibody Therapy Can Induce Long-Lasting Immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201214","article-title":"Immunotherapy During the Acute SHIV Infection of Macaques Confers Long-Term Suppression of Viremia","volume":"218","author":"Nishimura","year":"2021","journal-title":"J Exp Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1009339","DOI":"10.1371\/journal.ppat.1009339","article-title":"TLR7 Agonist, N6-LS and PGT121 Delayed Viral Rebound in SHIV-Infected Macaques After Antiretroviral Therapy Interruption","volume":"17","author":"Hsu","year":"2021","journal-title":"PloS Pathog"},{"key":"B71","article-title":"PGT121 and Vesatolimod in Chronically Treated SHIV-Infected Rhesus Monkeys","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Barouch","year":"2020"},{"key":"B72","article-title":"Combination IL-15 Therapy in a SHIV Nhp Model","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Lim","year":"2020"},{"key":"B73","article-title":"Combined ACTIVE and PASSIVE Immunization IN SHIV-Infected RHESUS Monkeys","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Barouch","year":"2020"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0747-1","article-title":"Combination Anti-HIV-1 Antibody Therapy Is Associated With Increased Virus-Specific T Cell Immunity","volume":"26","author":"Niessl","year":"2020","journal-title":"Nat Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy242","article-title":"Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective Art","volume":"5","author":"Riddler","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small Anti-Viral Compounds Activate Immune Cells Via the TLR7 MyD88-Dependent Signaling Pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01369-16","article-title":"Tlr7 Agonist Gs-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells","volume":"61","author":"Bam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01748-17","article-title":"Alt-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment","volume":"92","author":"Ellis-Connell","year":"2018","journal-title":"J Virol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e1008339","DOI":"10.1371\/journal.ppat.1008339","article-title":"The Human IL-15 Superagonist N-803 Promotes Migration of Virus-Specific CD8+ T and NK Cells to B Cell Follicles But Does Not Reverse Latency in ART-Suppressed, SHIV-Infected Macaques","volume":"16","author":"Webb","year":"2020","journal-title":"PloS Pathog"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-1946-0","article-title":"Robust and Persistent Reactivation of SIV and HIV by N-803 and Depletion of CD8(+) Cells","volume":"578","author":"McBrien","year":"2020","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2013.02.005","article-title":"Reactivation of Latent HIV by Histone Deacetylase Inhibitors","volume":"21","author":"Shirakawa","year":"2013","journal-title":"Trends Microbiol"},{"key":"B82","article-title":"A Randomized Trial of the Impact of 3BNC117 and Romidepsin on the HIV-1 Reservoir","volume-title":"Conference on Retroviruses and Opportunistic Infections (Croi)","author":"Gruell","year":"2020"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"New Engl J Med"},{"key":"B84","article-title":"Potent Antiviral Acitivity of Lenacapavir in Phase 2\/3 in Heavily Art-Experienced Pwh","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Segal-Maurer","year":"2021"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1008179","DOI":"10.1371\/journal.ppat.1008179","article-title":"Molecular Dating and Viral Load Growth Rates Suggested That the Eclipse Phase Lasted About a Week in HIV-1 Infected Adults in East Africa and Thailand","volume":"16","author":"Rolland","year":"2020","journal-title":"PloS Pathog"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30052-9","article-title":"Recommendations for Analytical Antiretroviral Treatment Interruptions in HIV Research Trials-Report of a Consensus Meeting","volume":"6","author":"Julg","year":"2019","journal-title":"Lancet HIV"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz090","article-title":"Human Immunodeficiency Virus Transmission Risk in Analytical Treatment Interruption Studies: Relational Factors and Moral Responsibility","volume":"220","author":"Dawson","year":"2019","journal-title":"J Infect Dis"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2017-104433","article-title":"Ethics of Treatment Interruption Trials in HIV Cure Research: Addressing the Conundrum of Risk\/Benefit Assessment","volume":"44","author":"Henderson","year":"2018","journal-title":"J Med Ethics"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000489","article-title":"Ethical Issues in HIV Remission Trials","volume":"13","author":"Eyal","year":"2018","journal-title":"Curr Opin HIV AIDS"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.710044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,12]],"date-time":"2021-07-12T08:29:05Z","timestamp":1626078545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.710044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,12]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2021.710044"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.710044","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,12]]},"article-number":"710044"}}